Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Merkel

Showing results (11-20 of 434) with videos related to

Pageof 44
Sort By:
Arthritis and Rheumatism|November 1, 2006
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosisEugene Y Kissin, Peter A Merkel, Robert Lafyatis
Current Opinion in Rheumatology|November 19, 2014
Outcome measures for Takayasu's arteritisSibel Z Aydin, Peter A Merkel, Haner Direskeneli
Annals of the Rheumatic Diseases|February 5, 2021
Response to: 'Correspondence on 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'' by Parikh <i>et al</i>Rona M Smith, Peter A Merkel, David Jayne
The Journal of Rheumatology|September 3, 2017
Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi ExerciseSibel Z Aydin, Haner Direskeneli, Peter A Merkel, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Assessment of disease activity and progression in Takayasu's arteritisHaner Direskeneli, Sibel Z Aydin, Peter A Merkel
Rheumatology (Oxford, England)|August 20, 2013
Disease assessment in Takayasu's arteritisHaner Direskeneli, Sibel Z Aydin, Peter A Merkel
The New England Journal of Medicine|May 29, 2024
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. ReplyMichael E Wechsler, Ying Fan, Peter A Merkel
Current Opinion in Rheumatology|December 17, 2008
Thromboembolic disease in vasculitisGunnar Tomasson, Paul A Monach, Peter A Merkel
Arthritis Care & Research|June 18, 2010
Patient-reported outcome assessment in vasculitis may provide important data and a unique perspectiveKaren Herlyn, Bernhard Hellmich, Philip Seo, et al.
Arthritis and Rheumatism|December 30, 2009
Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven reviewPaul A Monach, Lindsay M Arnold, Peter A Merkel
Pageof 44

Showing results (11-20 of 434) with videos related to

Sort By:
Pageof 44
Arthritis and Rheumatism|November 1, 2006
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosisEugene Y Kissin, Peter A Merkel, Robert Lafyatis
Current Opinion in Rheumatology|November 19, 2014
Outcome measures for Takayasu's arteritisSibel Z Aydin, Peter A Merkel, Haner Direskeneli
Annals of the Rheumatic Diseases|February 5, 2021
Response to: 'Correspondence on 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'' by Parikh <i>et al</i>Rona M Smith, Peter A Merkel, David Jayne
The Journal of Rheumatology|September 3, 2017
Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi ExerciseSibel Z Aydin, Haner Direskeneli, Peter A Merkel, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Assessment of disease activity and progression in Takayasu's arteritisHaner Direskeneli, Sibel Z Aydin, Peter A Merkel
Rheumatology (Oxford, England)|August 20, 2013
Disease assessment in Takayasu's arteritisHaner Direskeneli, Sibel Z Aydin, Peter A Merkel
The New England Journal of Medicine|May 29, 2024
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. ReplyMichael E Wechsler, Ying Fan, Peter A Merkel
Current Opinion in Rheumatology|December 17, 2008
Thromboembolic disease in vasculitisGunnar Tomasson, Paul A Monach, Peter A Merkel
Arthritis Care & Research|June 18, 2010
Patient-reported outcome assessment in vasculitis may provide important data and a unique perspectiveKaren Herlyn, Bernhard Hellmich, Philip Seo, et al.
Arthritis and Rheumatism|December 30, 2009
Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven reviewPaul A Monach, Lindsay M Arnold, Peter A Merkel
Pageof 44